Homepage Top Section2

Entrectinib has been granted priority review for the treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors in adult and paediatric patients. The

Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at

The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced

In the complete response letter (CRL) it issued to the company, the FDA said that it cannot approve the New Drug Application (NDA) of iclaprim in its present

Egaten is claimed to be the only FDA-approved drug to treat fascioliasis, which is a neglected tropical disease. Fascioliasis, which is commonly known as liver fluke infestation, is

Selonsertib has failed to meet the pre-specified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH. Stellar-4 is a phase 3

The 24 May is the new Prescription Drug User Fee Act (PDUFA) target action date for Jakafi, which is the treatment for patients with GVHD who have had

The M7824 is an investigational bifunctional fusion protein immunotherapy, which is currently under clinical development, including potential registration studies, for multiple difficult-to-treat cancers. Bintrafusp alfa is said to

The approval being sought from the US Food and Drug Administration (FDA) is for the post-surgery use of Kadcyla in patients with HER2-positive early breast cancer with residual